Alprostadil lyophilized liposomal

Drug Profile

Alprostadil lyophilized liposomal

Alternative Names: Prostaglandin E1 lyophilized liposomal

Latest Information Update: 02 Oct 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BioSphere Technologies; Harvard Scientific Corporation
  • Developer BioSphere Technologies; Harvard Scientific Corporation; Sae Han Pharmaceuticals
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Erectile dysfunction; Female sexual dysfunction; Male sexual dysfunction; Psoriasis

Most Recent Events

  • 02 Oct 2001 No-Development-Reported for Erectile dysfunction in European Union (Intrameatal)
  • 02 Oct 2001 No-Development-Reported for Erectile dysfunction in South Korea (Intrameatal)
  • 02 Oct 2001 No-Development-Reported for Erectile dysfunction in USA (Intrameatal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top